Impact of ITP on physician visits and workplace productivity

References

• Cines DB, Blanchette VS. Immune thrombocytopenic purpura. New Engl J Med 2002;346:995-1008
   PubMed Web of Science ®Google Scholar
• Rodeghiero F. Idiopathic thrombocytopenic purpura: an old disease revisited in the era of evidence-based medicine. J Hematol 2003;88:1081-7
   Google Scholar
• Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113:2386-93
   PubMed Web of Science ®Google Scholar
• British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Brit J Hematol 2003;120:574-96
   PubMed Web of Science ®Google Scholar
• McMillan R. Chronic idiopathic thrombocytopenic purpura. New Engl J Med 1981;304:1135-47
   PubMed Web of Science ®Google Scholar
• Segal JB, Powe NR. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost 2006;4:2377-83
   PubMed Web of Science ®Google Scholar
• Cines DB, McMillan R. Management of adult idiopathic thrombocytopenic purpura. Annu Rev Med 2005;56:425-42
   PubMed Web of Science ®Google Scholar
• Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood 2005;106:2244-51
   PubMed Web of Science ®Google Scholar
• Bussel J. Treatment of immune thrombocytopenic purpura in adults. Semin Hematol 2006;43:S3-S1014
   PubMed Web of Science ®Google Scholar
• George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88:3-40
   PubMed Web of Science ®Google Scholar
• George JN. Treatment options for chronic idiopathic (immune) thrombocytopenic purpura. Semin Hematol 2000;37:31-4
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008;371:395-403
   PubMed Web of Science ®Google Scholar
• Bussel JB, Prvan D, Shamsi R, et al. Effect of eltrombopaq on platelet counts and bleeding during the treatment of chronic idiopathic thrombocytopenic purpura: a randomized, double-blind, placebo-controlled trial. Lancet 2009;373:641-8
   PubMed Web of Science ®Google Scholar
• George JN, Kojouri K, Perdue JJ, et al. Management of patients with chronic, refractory idiopathic thrombocytopenic purpura. Semin Hematol 2000;37:290-8
   PubMed Web of Science ®Google Scholar
• Sandler SG, Novak SC, Roland B. The cost of treating immune thrombocytopenic purpura using intravenous Rh immune globulin versus intravenous immune globulin. Am J Hematol 2000;63:156-8
   PubMed Web of Science ®Google Scholar
• Simpson KN, Coughlin CM, Eron J, et al. Idiopathic thrombocytopenia purpura: treatment patterns and an analysis of cost associated with intravenous immunoglobulin and anti-D therapy. Semin Hematol 1998;35:58-64
   PubMed Web of Science ®Google Scholar
• Bennett CL, Weinberg PD, Golub RM, et al. The potential for treatment of idiopathic thrombocytopenic purpura with anti-D to prevent splenectomy: a predictive cost analysis. Semin Hematol 2000;37:26-30
   PubMed Web of Science ®Google Scholar
• Mahadevia PJ. The pocketbook: pharmacoeconomic issues related to intravenous immunoglobulin therapy. Pharmacotherapy 2005;25:94S-100S
   PubMed Web of Science ®Google Scholar
• Goetzel RZ, Long SR, Ozminkowski RJ, et al. Health, Absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting U.D. Employers. J Occup Environ Med 2004;46:398-412
   PubMed Web of Science ®Google Scholar
• Collins JJ, Baase CM, Sharda CE, et al. The assessment of chronic health conditions on work performance, absence, and total economic impact for employers. J Occup Environ Med 2005;47:547-57
   PubMed Web of Science ®Google Scholar
• Bottiger LE, Westerholm B. Thrombocytopenia I. Incidence and aetiology. Acta Med Scand 1972;191:535-40
   PubMed Web of Science ®Google Scholar
• Snyder CF, Mathias SD, Cella D, et al. Health-related quality of life in immune thrombycytic purpura patients: results from a web-based survey. Curr Med Res Opin 2008;24:2767-76
   PubMed Web of Science ®Google Scholar
• Mathias SD, Bussel JB, George JN, et al. A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validation. Health Qual Life Outcomes 2007;5:11
   PubMed Web of Science ®Google Scholar
• Mathias SD, Bussel JB, George JN, et al. A disease-specific measure of health-related quality of life in chronic immune thrombocytopenic purpura: psychometric testing in an open-label clinical trial. Clin Ther 2007;29:950-62
   PubMed Web of Science ®Google Scholar
• Holm, S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979;6:65-70
   Web of Science ®Google Scholar
• Yohannes AM, Roomi J, Waters K, et al. Quality of life in elderly patients with COPD: measurement and predictive factors. Respir Med 1998;92:1231-6
   PubMed Web of Science ®Google Scholar
• Esbensen BA, Osterlind K, Hallberg IR. Quality of life of elderly persons with cancer: a 3-month follow-up. Cancer Nurs 2006;29:214-24
   PubMed Web of Science ®Google Scholar
• McMillan R, Bussel JB, George JN, et al. Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol 2008;83:150-4
   PubMed Web of Science ®Google Scholar